Loading
A phase 2 trial of Brentuximab vedotin, Cyclophosphamide, Doxorubicin and Prednisone in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) is a phase 2 interventional study registered as NCT05673785 by Takeda, with 52 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2025-04-27. Interventions recorded: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
52 enrolled.
95% CI 86.8 to 99.5; Figures from the ClinicalTrials.gov results section (first posted 2026-06-12), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphomaprimary | Brentuximab Vedotin + CHP | 52 | 96.2% | - | - | link |
Shares Prednisone, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Doxorubicin, Cyclophosphamide and the tag pipeline.
Shares Takeda, Brentuximab vedotin, Doxorubicin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Takeda, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Prednisone, Doxorubicin, Cyclophosphamide and the tag pipeline.